SpyGlass Pharma, Inc. SGP
32.04 USD -0.84 (-2.55%)
As ofNov 16, 2026, 3:59 PM EST
29.16 Day range 32.81
17.06 52-week range 39.92
- YTD
- +21.36%
- 1 year
- +21.36%
News
benzinga.com Citigroup Maintains Buy on SpyGlass Pharma, Raises Price Target to $45 Citigroup analyst Yigal Nochomovitz maintains SpyGlass Pharma (NASDAQ:SGP) with a Buy and raises the price target from $42 to $45.
benzinga.com Stifel Maintains Buy on SpyGlass Pharma, Raises Price Target to $44 Stifel analyst Tom Stephan maintains SpyGlass Pharma (NASDAQ:SGP) with a Buy and raises the price target from $42 to $44.
benzinga.com HC Wainwright & Co. Maintains Buy on SpyGlass Pharma, Raises Price Target to $43 HC Wainwright & Co. analyst Yi Chen maintains SpyGlass Pharma (NASDAQ:SGP) with a Buy and raises the price target from $37 to $43.
benzinga.com SpyGlass Pharma Q3 EPS $(0.73) Misses $(0.63) Estimate SpyGlass Pharma (NASDAQ:SGP) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.63) by 15.87 percent. This is a 83.89 percent increase over losses of…
globenewswire.com SpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Updates IRVINE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business…benzinga.com HC Wainwright & Co. Reiterates Buy on SpyGlass Pharma, Maintains $37 Price Target HC Wainwright & Co. analyst Yi Chen reiterates SpyGlass Pharma (NASDAQ:SGP) with a Buy and maintains $37 price target.
benzinga.com SpyGlass Pharma Announces Trial Results From Bimatoprost Drug Pad-IOL System In Participants With Mild-To-Moderate Open Angle Glaucoma Reduces Mean IOP By 37% Across All Three Dose Cohorts; 86% Participants Remained Off All Topical IOP-Lowering Drops SpyGlass Pharma, Inc. (Nasdaq: SGP) ("SpyGlass Pharma" or "Company"), a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye
